Jenny is the Founder and Managing Director of Genoa Ventures, where she leverages her unique toolkit of genetics domain expertise, strategic business acumen, and venture investing to launch and empower the next generation of category-defying companies at the convergence of biology and technology.

She has over fifteen years of investing experience, beginning at Fidelity Biosciences in 2006 as a Kauffman Fellow. After Fidelity, Jenny helped establish the investing function at the Gates Foundation, funding companies in genetic engineering, diagnostics, and synthetic biology. Jenny began 5 Prime Ventures in 2014 using the largest life sciences syndicate on AngelList, and achieving one of the highest-performing AngelList syndicates of any sector.

Her prior investments include Zymergen (NASDAQ:ZY), Caribou (NASDAQ:CRBU), Intabio (acquired by Danaher Sciex), Accuri (acquired by Becton Dickinson), and Topaz (acquired by Sanofi).

Prior to her investing career, Jenny was a management consultant with McKinsey for the pharma and biotech sector. She also served in executive management roles at U.S. Genomics, leading Corporate Development and Research & Development. Jenny studied physics and software engineering at Georgia Tech and has a PhD in genetics from Yale University, where she was a National Science Foundation Fellow.